Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Malignant Solid Tumor 1Breast Neoplasms 1

Interventions

Cytarabine 81Azacitidine 66venetoclax 55fludarabine 34fludarabine phosphate 31Decitabine 28Cyclophosphamide 28Idarubicin 24Peripheral Blood Stem Cell Transplantation 22Filgrastim 20Granulocyte Colony-Stimulating Factor 18Busulfan 18Mitoxantrone 16Etoposide 16Whole-Body Irradiation 15Mycophenolic Acid 14Cyclosporine 14Tacrolimus 13Melphalan 13Daunorubicin 13Clofarabine 13Methotrexate 12gilteritinib 11aldesleukin 11plerixafor 10Injections 10decitabine and cedazuridine drug combination 9Gemtuzumab 9Cladribine 9quizartinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myeloid, Acute × Ribavirin × Clear all
NCT01056523 2023-10-02

Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia

Jewish General Hospital

Phase 1/2 Completed
29 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03760666 2022-08-08

A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Clear Creek Bio, Inc.

Phase 1/2 Terminated
17 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡